GSK has completed the acquisition of US vaccine developer Affinivax in a deal worth up to $3.3bn. Completion of the deal was announced to the London Stock Exchange this morning. Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. Under the terms of the … Continue reading GSK complete $3.3bn acquisition of US vaccine developer Affinivax